Compare MRVI & LZM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRVI | LZM |
|---|---|---|
| Founded | 2014 | 2021 |
| Country | United States | Isle of Man |
| Employees | N/A | 93 |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Mining |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 559.0M | 460.6M |
| IPO Year | 2020 | N/A |
| Metric | MRVI | LZM |
|---|---|---|
| Price | $4.83 | $5.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $4.13 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 1.8M | 929.4K |
| Earning Date | 05-07-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.29 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $185,743,000.00 | N/A |
| Revenue This Year | $12.54 | $86.37 |
| Revenue Next Year | $7.87 | $202.49 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.99 | $3.06 |
| 52 Week High | $4.11 | $6.40 |
| Indicator | MRVI | LZM |
|---|---|---|
| Relative Strength Index (RSI) | 80.65 | 69.42 |
| Support Level | $3.27 | $3.83 |
| Resistance Level | N/A | $6.15 |
| Average True Range (ATR) | 0.23 | 0.42 |
| MACD | 0.10 | 0.07 |
| Stochastic Oscillator | 98.48 | 84.94 |
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
Lifezone Metals Ltd seeks to support the clean energy transition through the licensing of Hydromet Technology as an alternative to smelting and metals refining. Its business comprises three segments: Metals extraction and refining for developing and operating a vertically integrated base metal operation in the northwest region of Tanzania, and Intellectual property licensing comprises patents residing with and managed by the subsidiary and corporate. Geographically, the company operates in South Africa, Australia, and the rest of the world. The majority of its revenue is generated from Australia.